A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

NCT00490971 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

768

Enrollment

INDUSTRY

Sponsor class

Conditions

Bipolar Disorder

Interventions

DRUG: Olanzapine
DRUG: Paliperidone ER
DRUG: Placebo

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.